Hudson Bay Capital Management LP Fibrogen Inc Transaction History

Hudson Bay Capital Management LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.73 - $2.73 $262,800 - $982,800	360,000 New	360,000 $846,000
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $331,750 - $443,250	-25,000 Reduced 16.67%	125,000 $2 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $370,500 - $474,500	-32,500 Reduced 17.81%	150,000 $1.95 Million
Q2 2022 Aug 12, 2022	BUY	$7.94 - $12.96 $337,450 - $550,800	42,500 Added 30.36%	182,500 $1.93 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.79 $60,100 - $83,950	5,000 Added 3.7%	140,000 $1.68 Million
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $49,650 - $76,950	-5,000 Reduced 3.57%	135,000 $1.9 Million
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $1.43 Million - $3.73 Million	140,000 New	140,000 $1.43 Million
Q4 2020 Feb 12, 2021	SELL	$37.09 - $48.97 $2.23 Million - $2.94 Million	-60,000 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$40.47 - $45.5 $2 Million - $2.24 Million	-49,310 Reduced 45.11%	60,000 $2.47 Million
Q2 2020 Aug 12, 2020	BUY	$32.57 - $42.83 $2.82 Million - $3.7 Million	86,484 Added 378.88%	109,310 $4.43 Million
Q1 2020 May 14, 2020	BUY	$23.3 - $45.96 $531,845 - $1.05 Million	22,826 New	22,826 $793,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.